atazanavir
chemical compound
≈ 5 min read
atazanavir. encyclopegia.org, snapshot atazanavir-048851-7607fe19ba611a32. /a/atazanavir
Names in other languages
- ไทยอะทาซานาเวียร์
- DeutschAtazanavir
- Englishatazanavir
- Nederlandsatazanavir
- Polskiatazanawir
- Portuguêsatazanavir
- SvenskaAtazanavir
- teఅటాజనవిర్
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
{{Drugbox | Verifiedfields = changed | verifiedrevid = 458476502 | image = Atazanavir structure.svg | image_class = skin-invert-image | width = 180 | alt = | image2 = Atazanavir ball-and-stick.png | image_class2 = bg-transparent | width2 = 220 | alt2 = | pronounce = | tradename = Reyataz, Evotaz, others | Drugs.com = | MedlinePlus = a603019 | DailyMedID = Atazanavir | pregnancy_AU = B2 | pregnancy_AU_comment = | routes_of_administration = By mouth | ATC_prefix = J05 | ATC_suffix = AE08 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_UK = POM | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | bioavailability = 60-68% | protein_bound = 86% | metabolism = Liver (CYP3A4-mediated) | elimination_half-life = 6.5 hours | excretion = Fecal and kidney | CAS_number_Ref = | CAS_number = 198904-31-3 | PubChem = 148192 | DrugBank_Ref = | DrugBank = DB01072 | ChemSpiderID_Ref = | ChemSpiderID = 130642 | UNII_Ref = | UNII = QZU4H47A3S | KEGG_Ref = | KEGG = D01276 | KEGG2_Ref = | KEGG2 = D07471 | ChEBI_Ref = | ChEBI = 37924 | ChEMBL_Ref = | ChEMBL = 1163 | NIAID_ChemDB = 057755 | IUPAC_name = methyl N-[(1S)-1- {[(2S,3S)-3-hydroxy-4-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-N- {[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate | C=38 | H=52 | N=6 | O=7 | smiles = O=C(OC)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc3ccc(c2ncccc2)cc3)C(C)(C)C | StdInChI_Ref = | StdInChI = 1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1 | StdInChIKey_Ref = | StdInChIKey = AXRYRYVKAWYZBR-GASGPIRDSA-N }} Atazanavir, sold under the brand name Reyataz among others, is an antiretroviral medication used to treat HIV/AIDS. It is generally recommended for use with other antiretrovirals.
It may be used for post-exposure prophylaxis after a needlestick injury or other potential exposure. It is taken by mouth. Common side effects include headache, nausea, yellowish skin, abdominal pain, trouble sleeping, and fever.
Severe side effects include rashes such as erythema multiforme and high blood sugar. Atazanavir appears to be safe to use during pregnancy. It is of the protease inhibitor (PI) class and works by blocking HIV protease.
Atazanavir was approved for medical use in the United States in 2003. The combination atazanavir/ritonavir is on the World Health Organization's List of Essential Medicines. Atazanavir is available as a generic medication.
Medical uses
Atazanavir is used in the treatment of HIV. The efficacy of atazanavir has been assessed in a number of well-designed trials in ART-naive and ART-experienced adults. Atazanavir is distinguished from other protease inhibitors in that it has lesser effects on lipid profile and appears to be less likely to cause lipodystrophy.
There may be some cross-resistant with other protease inhibitors. When boosted with ritonavir it is equivalent in potency to lopinavir for use in salvage therapy in people with a degree of drug resistance, although boosting with ritonavir reduces the metabolic advantages of atazanavir.
Contraindications
Atazanavir is contraindicated in those with previous hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions). Additionally, atazanavir should not be given with alfuzosin, rifampin, irinotecan, lurasidone, pimozide, triazolam, orally administered midazolam, ergot derivatives, cisapride, St. John's wort, lovastatin, simvastatin, sildenafil, indinavir, or nevirapine.
Atazanavir inhibits the enzyme UDP glucuronosyltransferase (UGT) 1A1, thereby impacting the hepatic glucuronidation and elimination of bilirubin. As such atazanavir may not be prescribed to patients with UGT1A1 deficiencies (e.g. those who suffer from Gilbert's syndrome or Crigler–Najjar syndrome) in order to avoid the possibility of jaundice.
Synthesis
A couple of atazanavir syntheses were originally reported. Below is one of them. The condensation of p-bromobenzaldehyde [1122-91-4] (1) with methanol gives 4-bromobenzaldehyde dimethyl acetal [24856-58-4] (2).
Grignard reaction with the reagent from 2-bromopyridine [109-04-6] causes a coupling exactly like in the Ullmann reaction. The product from this step is called 2-(4-dimethoxymethylphenyl)pyridine [1033125-49-3]. After the hydrolysis of the acetal, the product is called 4-(2-pyridyl)benzaldehyde [127406-56-8] (3).
Condensation with tert-Butyl carbazate [127406-56-8] to form the respective hydrazone (PC29940792); reduction of the azo FG gives the hydrazine [198904-85-7] (4). This reaction with (2S,3S)-1,2-Epoxy-3-(Boc-amino)-4-phenylbutane [98737-29-2] (5) led to PC98076738 (6).
Removal of both the Boc protecting groups with acid gives the penultimate compound, i.e. (2R,3S)-3-amino-1-[amino-[(4-pyridin-2-ylphenyl)methyl]amino]-4-phenylbutan-2-ol, PC98008965 (7). The last step requires a double amide formation with 2 equivalents of methyl N-[(2S)-1-chloro-3,3-dimethyl-1-oxobutan-2-yl]carbamate (8). This completes the synthesis of atazanavir (9).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1351543005 under CC BY-SA 4.0; modifications have been made.